Analystreport

Regulus Therapeutics Inc (NASDAQ: RGLS) is now covered by analysts at Leerink Swann. They set an "outperform" rating and a $2.00 price target on the stock.

Regulus Therapeutics Inc.  (RGLS) 
Last regulus therapeutics inc. earnings: 3/12 04:37 pm Check Earnings Report
US:NASDAQ Investor Relations: regulusrx.com/investors